Cosmos Health Inc. reports record 9-month revenue of $54.3m (+19% YoY) and Q3 revenue of $17.4m, reaffirming FY2026…
Key takeaway
Cosmos Health Inc. reports record 9-month revenue of $54.3m (+19% YoY) and Q3 revenue of $17.4m, reaffirming FY2026 guidance above $90m
- Step 1 · The triggerCosmos Health reports record 9-month revenue of $54.3m (+19% YoY) and reaffirms FY2026 guidance above $90m, signaling operational execution at Cana Laboratories and CosmoFarm
- Step 2 · Knock-onupstream suppliers to contract manufacturing and pharmaceutical distribution see firmer order books and volume commitments through Q4
- Step 3 · Knock-onstretched balance sheet (debt ratio of 1, thin interest coverage) raises counterparty credit risk even as revenue grows — payables duration and cash conversion become the binding constraint
- Step 4 · Reaches youSME suppliers face a trade-off between volume upside and payment risk, requiring tighter credit management
The trigger is reported by the source below. The steps that follow are Branch²’s traced reasoning — how the shock could reach a business like yours, not a prediction.
Source: SEC EDGAR — Current filings
See what today’s news does to your business. Atri by Branch² — Early-warning intelligence for your businessThis is automated analysis for information only. It is not investment advice, not a recommendation, and not a solicitation to buy or sell any security. Branch² is not authorised or regulated. Do your own research.